SHAREHOLDER ALERT: Weiss Law Investigates Sesen Bio, Inc.

NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN), in connection with the proposed merger of the Company with Carisma Therapeutics Inc. ("Carisma"). Under the merger agreement, Carisma shareholders will receive newly issued shares of Sesen common stock pursuant to an exchange ratio formula set forth in the merger agreement. Immediately prior to the closing of the proposed merger, the Company's shareholders will be issued a contingent value right ("CVR") for each outstanding share of Sesen common stock held. Upon completion of the transaction, Sesen shareholders are expected to only own approximately 41.7% of the combined company, while Carisma shareholders are expected to own approximately 58.3%.

If you own Sesen shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/sesn 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

Weiss Law is investigating whether (i) Sesen's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates Sesen's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. 

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE Weiss Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED